Bone marrow transplantation for primary refractory acute leukaemia.

Abstract

Twenty-four patients with primary resistant acute leukaemia received bone marrow transplants (BMTs) from matched sibling, syngeneic, matched unrelated, or mismatched family donors as treatment for induction failure. Three (12.5%) patients are alive and well 2-10 years after transplantation. Four (16.7%) patients died of transplant-related complications early post-transplant and remission status could not be determined. Two patients did not achieve complete remission (CR) and died of cytomegalovirus pneumonitis 3 months post-transplant. One patient died of graft failure. CR was obtained in 17 of 20 (85%) evaluable patients after BMT. Ten of 17 (58.8%) patients achieving CR died of transplant-related complications 1-10 months post-transplant. Four of 17 (23.5%) patients who had achieved CR relapsed after transplant. We conclude that a high proportion of patients failing to achieve remission with aggressive conventional chemotherapy achieve CR with BMT and a small proportion become long-term survivors.

• Authors: J Mehta, R Powles, C Horton, S Milan, J Treleaven, D Tait, D Catovsky
• Journal: Bone marrow transplantation (Bone Marrow Transplant) Vol. 14 Issue 3 Pg. 415-8 (Sep 1994) ISSN: 0268-3369 [Print] England
• PMID: 7994265 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Cyclosporine
• Methotrexate

Topics

• Adolescent
• Adult
• Bone Marrow Transplantation (adverse effects)
• Child
• Child, Preschool
• Cyclosporine (therapeutic use)
• Drug Therapy, Combination
• Female
• Follow-Up Studies
• Graft Rejection
• Graft vs Host Disease (prevention & control)
• Humans
• Leukemia, Myeloid, Acute (mortality, therapy)
• Male
• Methotrexate (therapeutic use)
• Precursor Cell Lymphoblastic Leukemia-Lymphoma (mortality, therapy)
• Prospective Studies
• Remission Induction
• Survival Rate